9th Annual RNA Therapeutics

9th Annual RNA Therapeutics is organized by SMi Group and will be held during Feb 21 - 22, 2018 at Holiday Inn London - Kensington Forum, London, England, United Kingdom.

One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and evaluate with key industry leaders the lessons they’ve learnt whilst developing an RNA therapeutic.

Join us this February 2018, as SMi's RNA Therapeutics Conference brings together industry experts from leading RNA therapeutics companies to analyze and evaluate the latest advancements including SaRNA as a potential therapeutic for people with liver cancer, advances in targeted delivery of nucleotides beyond the liver and the latest developments in delivery systems

Conference Objectives are :

• Explore new strategies being utilized by industry professionals and scientific pioneers.
• Establish the latest developments and advancements in RNA delivery agents and RNA-based therapeutics.
• Evaluate clinical results and lesson that have been learnt during clinical trials, through case studies with leading RNA therapeutics companies.
• Enhance knowledge regarding patenting of therapeutics, in order to maximise commercial return.
• Hear from the MHRA about potential new and upcoming regulatory updates and how they might affect the industry

How Will You Benefit?

Network and learn from leading professionals such as:
• Nagy Habib, Head of HPB Surgery, Imperial College London and Co-Founder, MiNA Therapeutics
• Shalini Andersson, Senior Director Drug Metabolism and Pharmacokinetics, AstraZeneca RandD
• Ekkehard Leberer, Senior Director, Sanofi
• Jeffrey Ulmer, Head Preclinical RandD, GSK
• James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals
• Mariola Fotin-Mleczek, Chief Scientific Officer, CureVac
• Bob D. Brown, Chief Scientific Officer and Senior Vice President, Research, Dicerna Pharmaceuticals
• Oliver Rausch, VP Research and Development, Storm Therapeutics
• Kirsty Wydenbach, Senior Medical Assessor, Deputy Unit Manager, Clinical Trials Unit, MHRA

Some Featured Highlights will include:
• Hear from MiNA Therapeutics about their new pre-clinical data supporting the on-target mechanism of action of their pioneering new drug candidate MTL-CEBPA
• Learn how CureVac's sophisticated technologies and approaches have helped overcome limitations such as the instability of single-stranded RNA
• Discover STORM Therapeutics' innovative approach: Harnessing the power of RNA epigenetics to develop first-inclass drugs in oncology.

Additional details will be posted as soon as they are available.